Xinlitai (002294.SZ) announced that Salubris Biotherapeuti...
According to the Zhitong Finance App, Xinlitai (002294.SZ) announced that Salubris Biotherapeutics, Inc. (“Salubris Bio”) is the company's innovative biopharmaceutical research and development center in the United States. The company has achieved hierarchical control through its wholly-owned subsidiary Nootech International Co., Ltd. (“Hong Kong Novotel”) and other companies. In order to further support the development of innovative biopharmaceuticals and accelerate the overseas biopharmaceutical research and development process, the company plans to increase capital to Salubris Bio with self-raised capital of 35 million US dollars (or equivalent in other currencies, approximately RMB 255.5 million, subject to the actual exchange rate conversion amount at the time of investment).
After the capital increase is completed, the company's total investment in Salubris Bio will increase from RMB 7255.589 million to RMB 981.0589 million (ultimately based on the actual exchange rate conversion amount at the time of investment). Salubris Bio is still the company's holding subsidiary.